Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Noteworthy news out of Nvelop Therapeutics as they launch with $100M to advance research in gene editing using programmable, non-viral delivery platforms built on two in vivo validated approaches. https://t.co/JX1o1X8qwn
The untapped potential of gene editing therapies comes down to one major challenge: getting gene editors safely and efficiently into cells. Now, a startup run by former bluebird bio execs is emerging from stealth to reveal its solutions to the industry. https://t.co/IUUvfJoHqw
9April: How do gene editing pioneers @davidrliu and @JKeithJoung address the challenge of delivering genetic medicines--technologies being developed by newly-launched @nvelop_tx? Hear from CEO Jeff Walsh & CSO Melissa Bonner, PhD in my latest for @GENbio: https://t.co/5IDLrtyeIY
Nvelop Therapeutics, a new gene editing startup co-founded by David Liu and Keith Joung, has emerged from stealth mode with a $100 million seed round. The company, led by CEO Jeff Walsh and CSO Melissa Bonner, PhD, aims to address the major challenge in gene therapy: the safe and efficient delivery of genetic medicines to patients. Nvelop's approach involves the development of programmable, non-viral delivery platforms based on two in vivo validated approaches, including two viral-like particle (VLP) delivery platforms, leveraging early science from Liu's and Joung's labs. The startup is led by two former bluebird bio executives, indicating a strong leadership team. This launch marks a significant step forward in the gene therapy space, focusing on overcoming delivery challenges to unlock the potential of gene editing therapies.